Chapter 8. Biomimetic Adhesives for Clinical Applications

Torres, Jessica E.; Hollingshead, Sydney; Boucher, Dana; Liu, Julie C.

doi:10.1039/9781788012720-00210

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A popular commercially available sealant, TISSEEL® (Baxter Healthcare, Deerfield, IL), was tested against pcECM in this study due to its proven efficacy in stopping venous bleeds. TISSEEL®'s indication is for general hemostasis during surgery, 13,14 and specifically refers to sealing of colonic anastomoses 15,16 . However, its off‐label use is abundant, and it has been adopted for a wide array of applications including dural repair, 17 neurosurgery and peripheral nerve repair, 18–22 congenital heart defects, 23 and periodontal flap surgery 24 .…”

Section: Introductionmentioning

confidence: 99%

“…TISSEEL ® 's indication is for general hemostasis during surgery, 13,14 and specifically refers to sealing of colonic anastomoses. 15,16 However, its off-label use is abundant, and it has been adopted for a wide array of applications including dural repair, 17 neurosurgery and peripheral nerve repair, [18][19][20][21][22] congenital heart defects, 23 and periodontal flap surgery. 24 TISSEEL ® , referred to as "fibrin sealant" in this report, mimics a physiological clot by combining human sealer protein and human thrombin to form fibrin.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Photocurable extracellular matrix sealant for cessation of venous hemorrhage

Schepers,

Martindale,

Berman

et al. 2024

J Biomed Mater Res

View full text Add to dashboard Cite

Hemorrhage is the second leading cause of death in patients under 46 years of age in the United States. Cessation of hemorrhage prevents hemorrhagic shock and tissue hypoxia. Controlling the bleed via direct pressure or tourniquet is often the first line of defense, but long‐term care requires staples, hemostatic agents, or sealants that seal the vessel and restore blood flow. Here, we compare a new photocurable extracellular matrix sealant (pcECM) with low, medium, and high crosslink density formulations to a commercially available fibrin‐based sealant, TISSEEL®. pcECM has potential uses in surgical and remote settings due to room temperature storage conditions and fast preparation time. Here, we determine if pcECM sealant can stop venous hemorrhage in a murine model, adhere to the wound site in vivo throughout the wound‐healing process, and has the mechanical properties necessary for stopping hemorrhage. Adjusting pcECM crosslinking density significantly affected viscosity, swelling, burst strength, tensile strength, and elasticity of the sealant. 3‐Dimensional ultrasound volume segmentations showed pcECM degrades to 17 ± 8% of its initial implant volume by day 28. Initially, local hemodynamic changes were observed, but returned close to baseline levels by day 28. Acute inflammation was observed near the puncture site in pcECM implanted mice, and we observed inflammatory markers at the 14‐day explant for both sealants. pcECM and fibrin sealant successfully sealed the vessel in all cases, and consistently degraded over 14–28 days. pcECM is a durable sealant with tunable mechanical properties and possible uses in hemorrhage control and other surgical procedures.

show abstract